» Articles » PMID: 26134402

Identification of Key Amino Acids Responsible for the Distinct Aggregation Properties of Microtubule-associated Protein 2 and Tau

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2015 Jul 3
PMID 26134402
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The carboxyl-terminal sequence of tau composes the framework for its intracellular inclusions that appear in diverse neurodegenerative disorders known as tauopathies. However, microtubule-associated protein 2 (MAP2), which contains a homologous carboxyl-terminal sequence of tau, is undetectable in the mature tau inclusions. The mechanisms underlying this phenomenon have remained largely unknown. Here, we show that tau and MAP2 have different aggregation properties: tau aggregates to form filaments but MAP2 remains to be granules. Exchanging (221) YKPV(224) of tau (0N3R) near the PHF6 motif for (340) TKKI(343) of MAP2c profoundly changed aggregation properties, suggesting that the YKPV motif is important for filament formation, whereas the TKKI motif is for granule formation. Thus, these minimal sequences may determine the different fates of tau and MAP2 in the formation of inclusions in tauopathies. Tau and microtubule-associated protein 2 (MAP2) are homologous microtubule-associated proteins in neurons. So far, it is largely unknown why tau but not MAP2 is selectively involved in the filamentous inclusions (neurofibrillary tangles, NFT) formation in tauopathies, including Alzheimer's disease. In this study, we found that the difference of only two amino acids in tau and MAP2 sequences may determine their different fates in tauopathies. These results may lead to the elucidation of tau deregulation in pathological conditions.

Citing Articles

Structural basis of binding the unique N-terminal domain of microtubule-associated protein 2c to proteins regulating kinases of signaling pathways.

Bartosik V, Plucarova J, Lanikova A, Janackova Z, Padrta P, Jansen S J Biol Chem. 2024; 300(8):107551.

PMID: 39002671 PMC: 11367651. DOI: 10.1016/j.jbc.2024.107551.


A structural and dynamic visualization of the interaction between MAP7 and microtubules.

Adler A, Bangera M, Beugelink J, Bahri S, Ingen H, Moores C Nat Commun. 2024; 15(1):1948.

PMID: 38431715 PMC: 10908866. DOI: 10.1038/s41467-024-46260-5.


Tau and neurodegeneration.

Goedert M, Crowther R, Scheres S, Spillantini M Cytoskeleton (Hoboken). 2023; 81(1):95-102.

PMID: 38073060 PMC: 7615684. DOI: 10.1002/cm.21812.


Disease-specific tau filaments assemble via polymorphic intermediates.

Lovestam S, Li D, Wagstaff J, Kotecha A, Kimanius D, McLaughlin S Nature. 2023; 625(7993):119-125.

PMID: 38030728 PMC: 10764278. DOI: 10.1038/s41586-023-06788-w.


MAP2 caps tau fibrils and inhibits aggregation.

Holden M, Krzesinski B, Weismiller H, Shady J, Margittai M J Biol Chem. 2023; 299(7):104891.

PMID: 37286038 PMC: 10404690. DOI: 10.1016/j.jbc.2023.104891.


References
1.
Dehmelt L, Halpain S . The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 2005; 6(1):204. PMC: 549057. DOI: 10.1186/gb-2004-6-1-204. View

2.
Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H . Granular tau oligomers as intermediates of tau filaments. Biochemistry. 2007; 46(12):3856-61. DOI: 10.1021/bi061359o. View

3.
Cowan C, Mudher A . Are tau aggregates toxic or protective in tauopathies?. Front Neurol. 2013; 4:114. PMC: 3741634. DOI: 10.3389/fneur.2013.00114. View

4.
Nishiura C, Takeuchi K, Minoura K, Sumida M, Taniguchi T, Tomoo K . Importance of Tyr310 residue in the third repeat of microtubule binding domain for filament formation of tau protein. J Biochem. 2009; 147(3):405-14. DOI: 10.1093/jb/mvp181. View

5.
Miyasaka T, Ding Z, Gengyo-Ando K, Oue M, Yamaguchi H, Mitani S . Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol Dis. 2005; 20(2):372-83. DOI: 10.1016/j.nbd.2005.03.017. View